Casdin Capital 13F holdings, Q4 2023
Holdings as of December 31, 2023 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 36 US equity positions worth $1.0bn in its Q4 2023 13F filing. The largest position was RVMD at 16.2% of the reported book, followed by BLFS and SRPT. Against the Q3 2023 filing, it opened 2 new positions, added to 7 and reduced 8 among the top 36 holdings.
What did Casdin Capital own in Q4 2023? Top 36 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2023 |
|---|---|---|---|---|---|---|---|
| 1 | RVMD REVOLUTION MEDICINES INC | Healthcare | 16.2% | $163.9m | 5,714,775 | 216% | added |
| 2 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 14.0% | $141.5m | 8,707,165 | 12% | added |
| 3 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 9.6% | $97.1m | 1,006,500 | -0% | held |
| 4 | RLAY RELAY THERAPEUTICS INC | Healthcare | 8.0% | $81.3m | 7,387,943 | 7% | added |
| 5 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 4.4% | $44.5m | 1,091,867 | -13% | reduced |
| 6 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 4.4% | $44.2m | 1,450,000 | 23% | added |
| 7 | ILMN ILLUMINA INC | Healthcare | 4.3% | $43.6m | 313,000 | 1152% | added |
| 8 | VERVE THERAPEUTICS INC | 4.1% | $41.9m | 3,009,094 | 2% | added | |
| 9 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 3.7% | $37.3m | 195,000 | -3% | reduced |
| 10 | SOMALOGIC INC | 3.1% | $31.9m | 12,604,275 | 0% | held | |
| 11 | EXK EXACT SCIENCES CORP | Basic Materials | 3.1% | $31.1m | 420,000 | -9% | reduced |
| 12 | 2655787D BLUEPRINT MEDICINES CORP | 3.0% | $30.1m | 326,378 | -12% | reduced | |
| 13 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 2.8% | $28.6m | 1,577,108 | 0% | held |
| 14 | DNLI DENALI THERAPEUTICS INC | Healthcare | 2.8% | $27.9m | 1,300,000 | 0% | held |
| 15 | 4D MOLECULAR THERAPEUTICS IN | 2.1% | $20.9m | 1,033,811 | 0% | held | |
| 16 | TNYA TENAYA THERAPEUTICS INC | 2.0% | $20.7m | 6,381,377 | 0% | held | |
| 17 | BEAM BEAM THERAPEUTICS INC | Healthcare | 1.4% | $14.4m | 528,000 | -7% | reduced |
| 18 | ABCL ABCELLERA BIOLOGICS INC | Healthcare | 1.3% | $13.5m | 2,360,129 | 0% | held |
| 19 | TNGX TANGO THERAPEUTICS INC | Healthcare | 1.2% | $11.8m | 1,188,349 | -9% | reduced |
| 20 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 1.0% | $10.6m | 3,206,380 | 0% | held |
| 21 | AVIDITY BIOSCIENCES INC | 1.0% | $10.6m | 1,175,750 | -6% | reduced | |
| 22 | NGNE NEUROGENE INC | 1.0% | $10.2m | 524,616 | – | new | |
| 23 | PACB PACIFIC BIOSCIENCES CALIF IN | Healthcare | 1.0% | $10.2m | 1,035,859 | 0% | held |
| 24 | WGS GENEDX HOLDINGS CORP | Healthcare | 0.8% | $8.5m | 3,095,511 | 0% | held |
| 25 | FATE FATE THERAPEUTICS INC | Healthcare | 0.8% | $7.7m | 2,050,000 | 0% | held |
| 26 | CDXS CODEXIS INC | Healthcare | 0.6% | $6.1m | 2,000,000 | 567% | added |
| 27 | 2SEVENTY BIO INC | 0.5% | $5.0m | 1,182,623 | -42% | reduced | |
| 28 | ABSI ABSCI CORPORATION | 0.4% | $4.1m | 973,260 | 0% | held | |
| 29 | PRME PRIME MEDICINE INC | 0.3% | $3.3m | 367,175 | 0% | held | |
| 30 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 0.3% | $3.2m | 150,000 | – | new |
| 31 | GLUE MONTE ROSA THERAPEUTICS INC | 0.3% | $2.9m | 510,882 | 0% | held | |
| 32 | LAB STANDARD BIOTOOLS INC | Healthcare | 0.3% | $2.7m | 1,200,000 | 0% | held |
| 33 | EXSCIENTIA PLC | 0.1% | $1.4m | 213,900 | 0% | held | |
| 34 | LIANY LIANBIO | 0.1% | $922.7k | 206,415 | 0% | held | |
| 35 | SINGULAR GENOMICS SYSTEMS IN | 0.1% | $609.1k | 1,323,885 | 0% | held | |
| 36 | KRONOS BIO INC | 0.0% | $154.8k | 123,839 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.